ESMO 2024: Capecitabine Improves Survival Versus Chemotherapy in ER-Positive/HER2-Negative Metastatic Breast Cancer Following Progression on Endocrine Therapy
Overall survival also improved for those who previously received CDK4/6 inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.